Leao R, et al. - Experts conducted this trial to assess the ability of defined serum microRNAs (miRNA) for predicting residual viable nonseminoma germ cell tumors (NSGCT) following chemotherapy. During chemotherapy, miRNA levels were notably associated to the extent of disease and declined significantly after chemotherapy. The potential value of miR-371a-3p in predicting viable germ cell tumors (GCT) in residual masses post-chemotherapy was displayed in the findings.